On paper, South Africa's public health system offers a model for hypertension control: free blood pressure checks at primary care clinics, a national essential medicines list that includes first-line antihypertensives, and a network of nurses trained to manage chronic disease. In practice, the system has a recurring fault line. At many clinics in Gauteng province--the economic heartland around Johannesburg and Pretoria--antihypertensive medications routinely run out before the end of the month. Patients who have been screened, diagnosed, and started on treatment find themselves returning to a pharmacy counter with empty shelves.

Free Screening, Empty Shelves: The Hypertension Paradox in Gauteng's Public Clinics

Gauteng's public clinics have invested heavily in screening. Community health workers conduct door-to-door blood pressure checks, and clinic-based nurse-led services offer same-day testing. The result is a high detection rate: roughly one in three adults in the province has hypertension, and most have been diagnosed. But detection without sustained treatment yields little benefit. A 2023 report from the Gauteng Department of Health noted that medication stock-outs for chronic conditions, including hypertension, occurred in over 40% of facilities during the second half of the month.

The pattern is predictable. At the start of each month, clinics receive a fresh supply from provincial depots. By the third week, amlodipine, enalapril, and hydrochlorothiazide--the three most commonly prescribed antihypertensives in the public sector--begin to dwindle. Patients who miss their refill window face a choice: return the following week in hopes of a new shipment, or go without. Data from the District Health Information System show that hypertension-related visits to emergency departments in Gauteng public hospitals spike in the last ten days of the month, a pattern consistent with interrupted treatment.

For a patient like Thandi M., a 54-year-old domestic worker in Soweto, the cycle is exhausting. She was diagnosed two years ago after a routine screening at a mobile clinic. Her blood pressure was 160/100 mmHg. She started amlodipine 5 mg daily, and her readings dropped to 130/85 mmHg. But twice in the past year, she has run out of tablets for a week or more. "I go to the clinic and they say come back next Tuesday," she told a community health worker in an informal interview documented by a local NGO. "Some months I borrow from my neighbour who takes the same pill."

How South Africa's Public Programme Funds Medicines--and Where It Falls Short

South Africa's public health system covers roughly 84% of the population, funded primarily through general taxation and a small allocation from the National Health Insurance pilot. The national Essential Medicines List includes a range of antihypertensives, and the public-sector formulary is designed to be cost-effective. Central procurement through provincial depots should ensure bulk purchasing discounts and consistent supply. In theory, the system works. In practice, per-capita medicine budgets have not kept pace with the rising prevalence of hypertension, driven partly by an aging population and high rates of obesity and diabetes.

A 2022 study in the South African Medical Journal surveyed 120 public clinics in Cape Town and found that 30% had experienced a stock-out of amlodipine in the previous three months. The Western Cape, often considered better managed than other provinces, still struggled. In Gauteng, the situation is more acute. Provincial health department reports from 2024 indicate that the allocated budget for chronic disease medicines was underspent in the first quarter--not because demand was low, but because procurement delays and distribution bottlenecks left clinics without the funds to reorder on time.

The funding gap is compounded by a mismatch between supply and demand patterns. Clinics order medicines based on historical usage, but patient enrolment in chronic care programmes has grown faster than expected. The number of patients on antihypertensive therapy in Gauteng increased by roughly 15% between 2020 and 2024, while the medicine budget grew by less than 5% in real terms. As a result, clinics that serve high-volume populations--such as those in Tembisa, Alexandra, and Soweto--often exhaust their monthly allocation by the second week.

Mid-Month Crisis: The Rhythm of Stock-Outs and Its Consequences

The mid-month stock-out is not a random event; it is a predictable consequence of a rigid supply chain. Provincial depots typically distribute medicines to clinics in a single monthly delivery. If a clinic runs out early, there is no emergency resupply mechanism. Patients who miss the narrow refill window--often just the first two weeks of the month--must wait until the next delivery. For a condition that requires daily medication, a gap of one to two weeks can have serious consequences.

When antihypertensives are interrupted, blood pressure rises. A study from the University of the Witwatersrand followed 200 patients in Soweto who experienced a medication gap of at least seven days. Their mean systolic blood pressure increased by 12 mmHg after the gap, and 18% had readings above 180/110 mmHg--a hypertensive urgency that often requires emergency care. The same study found that hospital admissions for hypertensive crisis were 40% more likely during the last week of the month than the first.

The consequences extend beyond immediate risk. Repeated interruptions can lead to a phenomenon known as "rebound hypertension," in which blood pressure overshoots to levels higher than before treatment. This increases the long-term risk of stroke, heart failure, and kidney damage. South Africa already has one of the highest stroke mortality rates in sub-Saharan Africa, particularly among working-age adults. A 2021 analysis in The Lancet Global Health estimated that improving hypertension control to 50% could prevent roughly 80,000 cardiovascular deaths annually in the country.

Patients' Workarounds: Borrowing Tablets, Halving Doses, or Going Without

Faced with stock-outs, patients develop coping strategies that are rational in the short term but dangerous in the long term. Informal pill-sharing is common: patients who have a surplus from a previous month give tablets to neighbours or relatives who have run out. While this maintains continuity of treatment, it also means that the donor may run out early themselves. The doses may not match the recipient's prescription--amlodipine comes in 5 mg and 10 mg tablets, and swapping can lead to under- or over-dosing.

Another common workaround is halving tablets. Some patients split their daily dose to make a month's supply last six weeks. A 2023 survey of 300 patients in Gauteng clinics found that 22% reported cutting their tablets in half at least once in the previous year. While this may stretch the supply, it also reduces the dose, often below the therapeutic threshold. For patients on combination therapy--such as amlodipine plus an ACE inhibitor--halving one component can leave the other unchanged, creating an unbalanced regimen.

For those who cannot find a workaround, the fallback is to purchase medicines from private pharmacies. But the cost is prohibitive for many. A month's supply of amlodipine 5 mg costs roughly 50-80 rand (about US$3-5) in the private sector--a significant expense for a household living on a social grant of 500 rand per month. Some patients choose to prioritise other needs, such as food or transport, and skip their medication entirely. Community health workers in Gauteng report that non-adherence due to cost is a leading reason for uncontrolled blood pressure among their clients.

What the Evidence Says About Intermittent Treatment and Cardiovascular Risk

Intermittent treatment of hypertension is not the same as no treatment, but it is far from optimal. A meta-analysis of 15 cohort studies published in Hypertension in 2022 found that patients who missed 20% or more of their prescribed doses had a 2.3-fold higher risk of stroke compared with those who adhered consistently. The risk was particularly high for patients with comorbid conditions such as diabetes or chronic kidney disease. In South Africa, where the prevalence of HIV and tuberculosis adds further complexity, the consequences of interrupted antihypertensive therapy are magnified.

Some evidence suggests that even short gaps can trigger vascular inflammation and endothelial dysfunction, increasing the risk of plaque rupture and thrombosis. A small trial conducted in a Cape Town community health centre measured arterial stiffness in patients who had a two-week medication gap. After resuming treatment, their arterial stiffness remained elevated for several weeks, suggesting that the damage from interruption persists beyond the gap itself. The World Heart Federation has flagged treatment gaps as a priority area for cardiovascular disease prevention in low- and middle-income countries, calling for "supply chain resilience" as a core intervention.

There is also a counter-argument worth considering: some clinicians argue that intermittent treatment is better than complete abandonment. If a patient cannot afford a full month's supply, taking medication on alternate days may still provide some blood pressure reduction. However, this view is not supported by current guidelines. The South African Hypertension Society recommends consistent daily dosing, and the evidence for alternate-day regimens is limited to small, short-term studies that show only modest blood pressure lowering and do not assess hard outcomes like stroke or death.

Policy Levers That Could Smooth the Supply Chain and Reduce Stock-Outs

Several policy changes could reduce the frequency and impact of stock-outs. One of the most promising is multi-month dispensing. Instead of issuing a 30-day supply, clinics could provide stable patients with a 90-day supply, reducing the number of refill visits and the burden on the supply chain. The Western Cape Department of Health piloted this approach in 2021 for patients with well-controlled hypertension, and early results showed a reduction in stock-out incidents by roughly 25% and improved adherence rates. Gauteng has expressed interest in scaling the model, but implementation has been slow.

Another lever is improved forecasting and inventory management. Many provinces still rely on paper-based stock cards and manual ordering, which are prone to error and delay. The introduction of electronic logistics management systems, such as the one used in the Western Cape, has been associated with fewer stock-outs. A 2023 evaluation found that clinics using electronic systems had a 60% lower likelihood of running out of essential medicines compared with those using manual systems. However, rollout has been uneven, and many Gauteng clinics still operate with paper.

The National Health Insurance (NHI) plan, as outlined in the 2023 NHI Act, includes provisions for supply chain reform and the establishment of a centralised medicines procurement agency. If implemented effectively, this could standardise ordering, reduce duplication, and improve accountability. But the NHI's timeline remains uncertain, and the immediate challenge is in the provinces. Task-shifting--allowing nurses to prescribe and refill antihypertensives without a doctor's visit--could also ease bottlenecks. A study in KwaZulu-Natal found that nurse-initiated refills reduced waiting times and improved adherence, without compromising safety.

For the Patient at the End of the Line: What Changes Would Actually Help

At the clinic level, simple operational changes could make a difference. Ensuring that patients with well-controlled hypertension receive a three-month supply, as recommended by the World Health Organization, would protect them from mid-month gaps. SMS reminders for refill appointments--a low-cost intervention proven to improve adherence in other chronic disease programmes--could help patients plan their visits. Expanding community-based blood pressure monitoring, through community health workers who can check readings and provide basic counselling, would reduce the need for clinic visits and free up clinical staff for more complex cases.

Integration of hypertension care with other chronic disease services--such as diabetes and HIV clinics--could also improve efficiency. Patients who visit a clinic for antiretroviral therapy could have their blood pressure checked and receive a refill at the same visit, reducing the number of separate appointments and the risk of stock-out at any one point. A pilot programme in the Eastern Cape showed that integrated care increased the proportion of patients with controlled blood pressure from 32% to 51% over 18 months.

Ultimately, the problem of mid-month stock-outs is not a technical failure but a political and financial one. The medicines are affordable; a year's supply of amlodipine for one patient costs roughly 150 rand in the public sector. The systems exist; the Western Cape has shown that stock-outs can be reduced. The missing ingredient is sustained political will to allocate sufficient resources and enforce accountability. For the patient waiting in line at a Soweto clinic, the difference between a functioning system and a broken one is a matter of life and death. The cycle of free screening followed by empty pharmacy shelves must be broken not with pilot programmes alone, but with a commitment to ensuring that every patient diagnosed with hypertension can access the medicines they need, every month, without interruption. Without that commitment, the investment in screening will continue to yield diminished returns, and the human cost will remain high.